InMed Pharmaceuticals is pleased to welcome to the BayMedica team following its acquisition in October 2021.
Meet Philip Barr, our VP of Discovery Research. Phil talks about his career history which includes his role at Chiron Corporation – a company involved in cloning the HIV and Hepatitis C viruses for which one of the scientific leaders received a Nobel Prize. Phil’s extensive experience includes expertise in molecular biology, organic chemistry and yeast biosynthesis. He later became the CEO of Arriva Pharmaceuticals where he spearheaded the development of recombinant human alpha 1-antitrypsin for hereditary emphysema. Phil eventually co-founded BayMedica.
Phil has significant industrial scale experience with yeast, including ultra-low cost manufacturing of biofuels and specialty chemicals. He has specialized in the field of polyketide production in yeast. Significantly, the cannabinoids are members of the polyketide family of natural products. Notably he also holds over 50 issued patents, and has authored some 200 papers and book chapters in chemistry, yeast molecular biology and genetic engineering.
